Pursuant to Regulations 30 and 33 of the SEBI (LODR) Regulations, 2015, we wish to inform that the Board of Directors at its meeting held on 13th August 2025 approved the Unaudited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs' board, at its meeting on 13 August 2025, approved the unaudited financial results for Q1 FY26 (quarter ended 30 June 2025). Revenue from operations fell to ₹2,381.13 lakhs from ₹3,220.75 lakhs in the same quarter last year, a decline of about 26% year-on-year. Net profit dropped to ₹104.06 lakhs (EPS ₹1.38) from ₹163.08 lakhs (EPS ₹2.17), a fall of roughly 36% YoY. Sequentially, however, net profit improved about 16% over Q4 FY25. The board also approved increasing authorised share capital from ₹10 crore to ₹20 crore (creating 1 crore additional equity shares of ₹10 each), subject to shareholder approval. Additionally, the 37th AGM was rescheduled from 28 August 2025 to 27 September 2025 to accommodate operational and compliance timelines.
The sharp year-on-year drop in revenue and profit is a concern for shareholders, though the sequential improvement suggests some recovery. The doubling of authorised share capital signals potential fundraising plans ahead, which could lead to equity dilution in the future.